Characterization of bombesin/gastrin-releasing peptide receptors in membranes of MKN45 human gastric cancer

Binding of the radiolabeled bombesin analog [ 125I-Tyr 4]bombesin to crude cell membranes of MKN45 human gastric cancer grown in nude mice was investigated in vitro. Scatchard analyses of multipoint binding data, performed by complete displacement method demonstrated the presence of two classes of [...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer letters 1994-09, Vol.85 (1), p.111-118
Hauptverfasser: Halmos, Gabor, Pinski, Jacek, Szoke, Balazs, Schally, Andrew V.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Binding of the radiolabeled bombesin analog [ 125I-Tyr 4]bombesin to crude cell membranes of MKN45 human gastric cancer grown in nude mice was investigated in vitro. Scatchard analyses of multipoint binding data, performed by complete displacement method demonstrated the presence of two classes of [Tyr 4]bombesin binding sites. The high-affinity binding sites had a mean dissociation constant ( K d1) of 2.75 nM with a mean maximal binding capacity ( B max1) of 492 fmol/mg membrane protein, while the low-affinity binding sites showed a mean dissociation constant ( K d2) of 0.41 μM with a mean maximal binding capacity ( B max2) of 41.4 pmol/mg membrane protein. Binding of [ 125I-Tyr 4]bombesin was specific, reversible and linearly related to the protein concentration of tumor membrane. In displacement studies, the binding of radiolabeled [Tyr 4]bombesin was inhibited in a dose-dependent manner by gastrin releasing peptide (GRP)(14–27) and two synthetic antagonists of bombesin/GRP, RC-3095 and RC-3950-II. Both antagonists exhibited high affinity in nearly the same concentration range as GRP(14–27). The presence of receptors for bombesin/GRP on human gastric cancer membranes suggests that bombesin-like peptides may play a role in growth of gastric cancer.
ISSN:0304-3835
1872-7980
DOI:10.1016/0304-3835(94)90246-1